Seccia Veronica, D'Amato Maria, Scioscia Giulia, Bagnasco Diego, Di Marco Fabiano, Fadda Gianluca, Menzella Francesco, Pasquini Ernesto, Pelaia Girolamo, Tremante Eugenio, De Corso Eugenio, Bonini Matteo
Otolaryngology, Audiology and Phoniatric Operative Unit, Department of Surgical, Medical, Molecular Pathology and Critical Care Medicine, Pisa University Hospital, 56124 Pisa, Italy.
UOSD Malattie Respiratorie "Federico II", Ospedale Monaldi, AO Dei Colli, 80131 Napoli, Italy.
J Pers Med. 2022 Jul 1;12(7):1096. doi: 10.3390/jpm12071096.
Chronic rhinosinusitis (CRS) is one of the most frequent comorbidities associated with asthma and it contributes to an amplified global disease burden in asthmatics. CRS prevalence is much higher in asthmatic patients compared to the general population and it is more frequently related to severe asthma, especially in presence of nasal polyps (chronic rhinosinusitis with nasal polyps, CRSwNP). Moreover, asthma exacerbation has a higher occurrence in CRSwNP. From a pathologic point of view, CRS and asthma share similar and connected mechanisms (e.g., type-2 inflammation). A multidisciplinary approach represents a crucial aspect for the optimal management of patients with concomitant asthma and CRSwNP and improvement of patient quality of life. An Italian panel of clinicians with different clinical expertise (pulmonologists, ear, nose and throat specialists, immunologists and allergy physicians) identified three different profiles of patients with coexisting asthma and nasal symptoms and discussed the specific tracks to guide a comprehensive approach to their diagnostic and therapeutic management. Currently available biological agents for the treatment of severe asthma act either on eosinophil-centered signaling network or type-2 inflammation, resulting to be effective also in CRSwNP and representing a valid option for patients with concomitant conditions.
慢性鼻-鼻窦炎(CRS)是与哮喘相关的最常见合并症之一,它加剧了哮喘患者的全球疾病负担。与普通人群相比,哮喘患者中CRS的患病率要高得多,并且它更常与重度哮喘相关,尤其是在存在鼻息肉的情况下(伴有鼻息肉的慢性鼻-鼻窦炎,CRSwNP)。此外,CRSwNP中哮喘加重的发生率更高。从病理学角度来看,CRS和哮喘具有相似且相关的机制(例如2型炎症)。多学科方法是优化管理哮喘合并CRSwNP患者以及改善患者生活质量的关键因素。一个由具有不同临床专业知识的意大利临床医生组成的小组(肺科医生、耳鼻喉科专家、免疫学家和过敏科医生)确定了三种同时患有哮喘和鼻部症状的患者类型,并讨论了指导对其进行诊断和治疗管理的综合方法的具体思路。目前可用于治疗重度哮喘的生物制剂作用于以嗜酸性粒细胞为中心的信号网络或2型炎症,结果证明对CRSwNP也有效,是合并症患者的一个有效选择。